LOPREIATO, Mariangela
 Distribuzione geografica
Continente #
EU - Europa 120
NA - Nord America 112
AS - Asia 59
SA - Sud America 23
AF - Africa 1
Totale 315
Nazione #
US - Stati Uniti d'America 109
IT - Italia 77
SG - Singapore 26
BR - Brasile 19
DE - Germania 14
CN - Cina 12
FI - Finlandia 7
GB - Regno Unito 6
IN - India 6
NL - Olanda 6
VN - Vietnam 6
RU - Federazione Russa 3
ES - Italia 2
FR - Francia 2
HK - Hong Kong 2
AR - Argentina 1
BD - Bangladesh 1
BO - Bolivia 1
CA - Canada 1
CH - Svizzera 1
CO - Colombia 1
CZ - Repubblica Ceca 1
ID - Indonesia 1
IQ - Iraq 1
JO - Giordania 1
KR - Corea 1
LB - Libano 1
MX - Messico 1
PL - Polonia 1
TR - Turchia 1
TT - Trinidad e Tobago 1
VE - Venezuela 1
ZA - Sudafrica 1
Totale 315
Città #
Dallas 23
San Jose 15
Ashburn 14
Carbonia 12
Singapore 11
Munich 10
Chicago 6
Ho Chi Minh City 5
London 5
Bologna 4
Chandler 4
Ercolano 4
Santa Clara 4
Turku 4
Afragola 3
Bengaluru 3
Hefei 3
Helsinki 3
Los Angeles 3
Rome 3
Brescia 2
Frankfurt am Main 2
Hong Kong 2
Naples 2
New York 2
Paris 2
Reggio Calabria 2
San Nicola Manfredi 2
São Paulo 2
Ahmedabad 1
Alvorada 1
Amman 1
Arnhem 1
Balıkesir 1
Beijing 1
Beirut 1
Benevento 1
Bragança Paulista 1
Brasília 1
Brooklyn 1
Buffalo 1
Caicó 1
Caldas Novas 1
Catania 1
Catanzaro 1
Chaguanas 1
Charlotte 1
Chennai 1
Ciudad Bolívar 1
Cleveland 1
Cosenza 1
Crestview 1
Dolores Hidalgo 1
Hanoi 1
Hanover 1
Houston 1
Hyderabad 1
Isidro Casanova 1
Jacarezinho 1
Johannesburg 1
La Paz 1
Lajeado 1
Madrid 1
Manaus 1
Manchester 1
Melito di Porto Salvo 1
Milan 1
Mosul 1
Niterói 1
Norwich 1
Nova Iguaçu 1
Nuremberg 1
Osasco 1
Padang 1
Palermo 1
Parma 1
Petrópolis 1
Ponto Belo 1
Portland 1
Porto Alegre 1
Prague 1
Santo Stefano di Rogliano 1
Satuba 1
Sorrento 1
Soverato Marina 1
Squillace 1
St Petersburg 1
Torres 1
Ubá 1
Warsaw 1
Washington 1
Zipaquirá 1
Totale 220
Nome #
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 137
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 110
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 76
Totale 323
Categoria #
all - tutte 1.390
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.390


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202325 6 3 0 1 1 0 1 3 3 0 7 0
2023/202449 15 6 6 2 1 6 4 1 0 2 3 3
2024/2025111 11 2 2 5 5 12 6 5 9 2 25 27
2025/2026138 8 19 29 18 15 2 14 10 13 10 0 0
Totale 323